摘要
由于许多恶性肿瘤仍然无法治愈,所以新的治疗方式正迅速向临床使用。腺病毒(Ad)尤其在过去几十年被广泛研究作为常规癌症治疗的有希望的替代方法。尽管Ad在临床前模型中表现出有希望的治疗结果和癌症特异性,但由于几个缺点,如病毒颗粒通过宿主免疫应答快速清除,诱导急性炎症反应和肝毒性,其在临床试验中的疗效仍不足。在这方面,Ad与其他癌症治疗方式(如化学疗法,放射疗法或免疫疗法)的组合可以是克服Ad的限制的有效策略。通过Ad特异性和有效表达多功能治疗基因可增强其他治疗方式的治疗特征,使其成为抗恶性肿瘤的合并治疗的合理候选者
关键词: 联合治疗,腺病毒,溶瘤腺病毒,化疗,癌症,免疫治疗,放疗。
图形摘要
Current Cancer Drug Targets
Title:Emergence of Ad-Mediated Combination Therapy Against Cancer: What to Expect?
Volume: 18 Issue: 2
关键词: 联合治疗,腺病毒,溶瘤腺病毒,化疗,癌症,免疫治疗,放疗。
摘要: Novel treatment modalities are rapidly advancing toward clinical use as many malignant cancers still remain incurable. Adenovirus (Ad) in particular has been extensively researched as a promising alternative to conventional cancer therapy in the past decades. Although Ad has demonstrated promising therapeutic outcome and cancer specificity in preclinical models, its therapeutic efficacy in clinical trials is still insufficient due to several drawbacks such as rapid clearance of viral particles by host immune response, induction of acute inflammatory response, and hepatotoxicity. In this regard, combination of Ad with other cancer treatment modalities, such as chemotherapy, radiotherapy, or immunotherapy, can be an effective strategy to overcome the limitations of Ad. Cancerspecific and effective expression of multifunctional therapeutic genes by Ad can enhance the therapeutic profile of other treatment modalities, making it a logical candidate for combination therapy to combat malignant tumors.
Export Options
About this article
Cite this article as:
Emergence of Ad-Mediated Combination Therapy Against Cancer: What to Expect?, Current Cancer Drug Targets 2018; 18 (2) . https://dx.doi.org/10.2174/1568009617666170222123406
DOI https://dx.doi.org/10.2174/1568009617666170222123406 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Exogenous Expression of WNT7A in Leukemia-Derived Cell Lines Induces Resistance to Chemotherapeutic Agents
Anti-Cancer Agents in Medicinal Chemistry Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway
Current Topics in Medicinal Chemistry Targeting the STAT Pathway in Head and Neck Cancer: Recent Advances and Future Prospects
Current Cancer Drug Targets Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery Recent Advances of Small Molecule Focal Adhesion Kinase (FAK) Inhibitors as Promising Anticancer Therapeutics
Current Medicinal Chemistry Antioxidant, Pro-Oxidant and Other Biological Activities of Sesquiterpenes
Current Topics in Medicinal Chemistry Metformin Protects the Brain Against the Oxidative Imbalance Promoted by Type 2 Diabetes
Medicinal Chemistry Spectroscopic Characterization of a Pyridine Alkaloid from an Endophytic Strain of the Fusarium incarnatum-equiseti Species Complex
Current Bioactive Compounds Validation of Self-Report of Chest X-Ray Exam at a Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Center
Reviews on Recent Clinical Trials KRAB-Zinc Finger Proteins: A Repressor Family Displaying Multiple Biological Functions
Current Genomics Malignancy and Radiation-Induced Cardiotoxicity
Cardiovascular & Hematological Disorders-Drug Targets Restoring TRAIL Induced Apoptosis Using Naturopathy. Hercules Joins Hand with Nature to Triumph Over Lernaean Hydra
Current Genomics Metabolomics and the Diagnosis of Human Diseases -A Guide to the Markers and Pathophysiological Pathways Affected
Current Medicinal Chemistry Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology Idronoxil as an Anticancer Agent: Activity and Mechanisms
Current Cancer Drug Targets The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine Protective Effects of Curcumin against Lipopolysaccharide-Induced Toxicity
Current Medicinal Chemistry <I>In-silico</I> Molecular Interaction of Short Synthetic Lipopeptide/Importin-alpha and <I>In-vitro</I> Evaluation of Transgene Expression Mediated by Liposome- Based Gene Carrier
Current Gene Therapy Unique Biology of Mcl-1: Therapeutic Opportunities in Cancer
Current Molecular Medicine Monoclonal Antibodies as Cancer Therapeutics
Recent Patents on Biotechnology